Artiva Biotherapeutics, Inc. Price & Performance (ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV) has received a consensus "Buy" rating from six analysts, with an average price target of $21. This positive outlook reflects confidence in the company’s innovative NK cell-based therapies, particularly its lead product AB-101 targeting autoimmune diseases and cancers.12

Major U.S. stock indexes, including the S&P 500 and Nasdaq 100, hit six-month lows as escalating trade tensions triggered sell-offs. President Trump’s threats of new tariffs on European goods and refusal to repeal steel tariffs fueled investor concerns, overshadowing otherwise positive economic data.34

Artiva Biotherapeutics is conducting two trials for autoimmune diseases, including lupus and rheumatoid arthritis. One trial is company-sponsored, while the other tests feasibility in community settings. These efforts highlight Artiva’s strategy to expand NK cell therapy applications beyond traditional settings.56